BOPA 2018 | The emergence of mixed specialty oncology

The increased use of targeted therapies in oncology has introduced a range of new side effects. Emma Foreman, BPharma (Hons) of The Royal Marsden NHS Foundation Trust, London, UK, discusses how these side effects, for example cardiological, neurological or rheumatoid side effects, have introduced the need for Oncology Pharmacists to become more knowledgeable on other specialities. Ms Foreman thinks that there is a role for groups like the British Oncology Pharmacy Association (BOPA) to produce training and educational materials to help Oncology Pharmacists bridge these knowledge gaps. This interview was recorded at BOPA Annual Symposium 2018, held in Birmingham, UK.